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Abstract
Objective—Criteria to decide which pa-
tients with rheumatoid arthritis (RA)
should be examined by dual energy x ray
absorptiometry (DXA) are currently not
available. The rheumatologists from Am-
sterdam have proposed preliminary crite-
ria based on clinical risk factors (age,
disease activity, and functional status).
These criteria are preliminary and not
widely accepted but might be helpful in
practice. The value of the proposal in a
group of Spanish postmenopausal women
with RA is analysed.
Methods—DXA (lumbar spine and femo-
ral neck) was performed in 128 patients
recruited from a clinical setting, and the
proposed criteria were applied. T and Z
scores were established for a Spanish ref-
erence population.
Results—The mean (SD) age of the pa-
tients was 61.3 (10.7) and mean duration
of the postmenopausal period 14.5 (10.1)
years. Mean duration of RA was 13.7 (7.7)
years. Mean C reactive protein was 22 (21)
mg/l; mean erythrocyte sedimentation
rate 26 (18) mm/1st h; and mean Health
Assessment Questionnaire score 1.25
(0.79). Ninety (70%) patients fulfilled the
proposed criteria. Their sensitivity for the
diagnosis of osteoporosis (T score <−2.5
SD) was 86% and their specificity, 43%.
Positive predictive value was 54% and
negative predictive value, 79%.
Conclusions—The proposed criteria seem
a good screening method for the selection
of those patients with RA whose bone
mineral density should be assessed as the
sensitivity and negative predictive value
are acceptable.
(Ann Rheum Dis 2001;60:799–801)
Dual energy x ray absorptiometry (DXA) is the
most commonly used method of measuring
bone mineral density (BMD); it has been
shown to be a good predictor of the future risk
of fracture. Unfortunately, the generalised use
of DXA is limited as it is expensive and time
consuming, is not portable, and is available
only in specialised clinics.
Generalised bone loss is recognised as an
extra-articular complication in rheumatoid
arthritis (RA).1 There is compelling evidence
that this bone mass reduction is associated with
an increased risk of fracture.2 3
DXA is the preferred technique for assessing
the presence of low BMD in patients with RA.
However, the prevalence of RA in the general
population is high and it is, therefore, necessary
to use DXA to investigate only those patients at
high risk of osteoporosis.
Criteria to decide who should be evaluated
are currently not available. Of interest, Lems
and Dijkmans4 presented a proposal from
rheumatologists in Amsterdam based on clini-
cal risk factors (age, disease activity, and func-
tional status) strongly associated with low
BMD in patients with RA. This proposal is a
set of preliminary criteria to promote a discus-
sion on osteoporosis in RA; they are not widely
accepted guidelines. However, it is interesting
and may be helpful in daily rheumatological
practice until more definite criteria are avail-
able.
We have undertaken, in a group of Spanish
postmenopausal women, a study to evaluate
the value of the proposed criteria as a screening
method to identify the patients with RA who
should be examined by DXA.
Methods
Over a period of 12 months all postmenopausal
women who were receiving regular follow up
(three to six visits each year) for RA at the out-
patient clinic of our rheumatology department
and who fulfilled the inclusion criteria were
asked to participate. The inclusion criteria
were (a) duration of RA longer than one year;
(b) duration of postmenopausal period longer
than one year; and (c) absence of concomitant
diseases that might aVect BMD. Patients with
current or past treatment with 7.5 mg/day or
above of prednisone were excluded. Consent
was obtained from 128 patients. All the
included patients fulfilled the 1987 criteria of
the American Rheumatism Association for RA
diagnosis.5
The medical charts of the patients were
reviewed in order to record the data about (a)
age; (b) duration of the postmenopausal
period; (c) duration of RA; (d) rheumatoid fac-
tor; and (e) C reactive protein (CRP) and
erythrocyte sedimentation rate (ESR) in the
1st hour; the mean of the determination of
CRP and ESR in the past year was calculated.
BMD (g/cm2) was measured at the lumbar
spine (L2-4) and femoral neck by DXA using a
Hologic - QDR 1000 unit (Hologic Inc,
Waltham, Mass). Calibration with a lumbar
spine phantom was performed daily and with a
femoral phantom weekly. T and Z scores were
established in comparison with a reference
healthy Spanish population.6 World Health
Organisation7 criteria were used for the diagno-
sis of osteoporosis (T score <−2.5 SD).
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On the same day that BMD assessment was
made, the Spanish version8 of the Health
Assessment Questionnaire (HAQ) was applied
and Steinbrocker’s score was established.
Proposed criteria from rheumatologists in
Amsterdam were evaluated in each patient.
These criteria are the following: (a) high
disease activity, defined as mean CRP above 20
mg/l or persistently increased ESR above 20
mm/1st h, or both; (b) high age, defined for
women as >50 years and for men as >60 years;
and (c) immobility, defined as HAQ >1.25 or
Steinbrocker’s score >3, or both. If two or
more criteria are present evaluation of BMD is
recommended.
The results are expressed as mean (SD).
Confidence interval (CI) was used to assess the
diVerence between the mean Z score at each
site and the general population; p values <0.05
were considered significant. A 2 × 2 table was
used to evaluate the sensitivity, the specificity,
and the positive and negative predictive values
of the proposed criteria for the diagnosis of
osteoporosis established by DXA. Additionally,
their value for a T score <−1 (low bone mass)
and for a Z score <−1 was also calculated.
The patient’s ascription to each category was
made using the lowest value of the two regions
explored.
Results
Table 1 summarises the clinical characteristics
of the 128 patients included in the study.
Mean lumbar BMD was 0.856 (0.144)
g/cm2, mean lumbar T score was −1.74 (1.38),
and mean lumbar Z score was −0.21 (1.01)
(95%CI −0.39 to −0.03; p <0.05). At the
femoral neck, mean BMD was 0.645 (0.116)
g/cm2, mean T score −1.74 (1.13), and mean Z
score −0.57 (0.99) (95%CI −0.75 to −0.39; p
<0.05).
DXA showed that 20 (16%) patients had
normal BMD both in the lumbar spine and the
femoral neck. Fifty six (44%) patients had
osteoporosis in at least one of the evaluated
sites. One hundred and eight (84%) patients
had a T score <−1 and 51 (40%) patients a Z
score <−1.
A hundred and thirteen (88%) patients were
aged more than 50 years; 71 (55%) patients
presented a CRP above 20 mg/l or an ESR
above 20 mm/1st h, or both; 69 (54%) patients
had an HAQ >1.25 or a Steinbrocker’s score
>3, or both.
Five (4%) patients did not fulfil any of the
proposed criteria from the rheumatologists of
Amsterdam; 34 (27%) fulfilled one criteria; 47
(37%), two criteria; and 42 (33%), three crite-
ria. Thus 89 (70%) patients fulfilled two or
three criteria.
Table 2 shows the sensitivity, specificity,
positive predictive value, and negative predic-
tive value of the proposed criteria for the diag-
nosis of osteoporosis and for the identification
of the patients with a T score <−1 or a Z score
<−1.
Discussion
We have evaluated the proposal from rheuma-
tologists in Amsterdam in a group of Spanish
postmenopausal women with RA. Our study
should be interpreted in the light of several
considerations. The patients included are
recruited from a clinical setting. Their charac-
teristics probably do not represent the com-
plete underlying population of patients with
RA in the community. Unfortunately, there is
not an available population based study which
defines the overall characteristics of Spanish
patients with RA.
As expected, BMD of patients was lower
than that of the general population. The
percentage of osteoporosis was higher than that
seen in a recent population based study by
Haugeberg et al which evaluated the magnitude
of the problem in Norway.9 Possibly, examina-
tion of BMD reduction in a series of patients
who are referred to a rheumatology unit
overestimates the problem and establishes a
selection bias. Risk factors associated with low
BMD in RA are especially prevalent in patients
with aggressive disease, who are the subjects
usually followed up in a hospital; a large
percentage of these subjects had high disease
activity and a high degree of immobility, two of
the criteria proposed by the rheumatologists in
Amsterdam.4
The proposal is extensive for both male and
female patients. We examined only postmeno-
pausal women as it seems that this group of
patients with RA are particularly susceptible to
osteoporosis. They are usually older than 50;
thus one of the criteria is nearly always present
and thus not useful.
The proposed criteria focus particularly on
patients with RA not treated with corticoster-
oids, though it might be also useful in patients
receiving this treatment.10 Eighty five per cent
of our patients are currently treated with low
dose corticosteroids; this overrepresentation of
corticosteroid treatment is a consequence of
the kind of patients included in the study, peri-
odically followed up in a teaching hospital who
present with high clinical severity.
Our results suggest that the proposal of the
rheumatologists in Amsterdam may be a
Table 1 Clinical characteristics of 128 postmenopausal
women with RA.Values are expressed as mean (SD) or No
[%]
Age (years) 61.3 (10.7)
Duration of postmenopausal period (years) 14.5 (10.1)
Duration of rheumatoid arthritis (years) 13.7 (7.7)
Rheumatoid factor positive 96 [75]
Treatment with low dose corticosteroids 109 [85]
Erythrocyte sedimentation rate (mm/1st h) 26 (18)
C reactive protein (mg/l) 22 (21)
Health Assessment Questionnaire 1.25 (0.79)
Steinbrocker’s score
1 33 [26]
2 51 [40]
3 40 [31]
4 4 [3]
Table 2 Sensitivity, specificity, and predictive values of the
proposed criteria for each category
T score <−1 T score <−2.5 Z score <−1
Sensitivity (%) 75 86 78
Specificity (%) 60 43 36
PPV* (%) 91 54 45
NPV* (%) 31 79 71
*PPV = positive predictive value; NPV = negative predictive
value.
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screening method to decide which postmeno-
pausal women with RA should be investigated
for osteoporosis; the sensitivity and the nega-
tive predictive value obtained seem acceptable
in clinical practice. Specificity and positive pre-
dictive value were low, probably reflecting the
fact that multiple factors play a part in the
pathogenesis of osteoporosis in patients with
RA.
In practice, identification of patients with a T
score <−1 or with a Z score <−1 may be as
important as osteoporosis when considering
treatment or prevention. In fact, the impor-
tance of diVerent cut oV levels has not been
definitively clarified in patients with RA in
relation to subsequent fractures. Thus we
tested the sensitivity and specificity as well as
predictive values of the proposed criteria in our
patient group also considering these two end
points.
Recently, Kvien et al published an interesting
population based study which examined rela-
tions among osteoporosis and low bone mass
and demographic and clinical variables in
patients with RA, in an attempt to develop a
data driven clinical tool for the identification of
patients at high risk for osteoporosis.11 The
logistic regression analysis models could only
predict osteoporosis with a sensitivity of
50–60% and a specificity of 80–90% at the
various measurement sites, and low bone mass
with a sensitivity and specificity of about 70%.
The authors stated that a consideration of
demographic and disease markers may be of
some help in predicting the presence of
osteoporosis or low bone mass, but a combina-
tion of markers cannot be used as a clinical tool
with suYcient sensitivity and specificity for the
identification of osteoporosis or low bone mass
in patients with RA.
A population based study to analyse the
value of the proposal from the rheumatologists
in Amsterdam would be particularly welcome
in order to establish a comparison with the
results obtained in our study.
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